Seer Q3 2024 revenue $4.0M, net loss $21.3M; FY guidance reaffirmed $13-15M

Seer, Inc.

2024-Q3 EPS reported -$1.02 revenue$10,170,000

Q3 revenue $4.0M vs $4.2M YoY (down 3%); product revenue $3.1M, service $847K, grant $90K.
Net loss $21.3M vs $21.1M YoY; gross margin 48%; operating expenses down 6% to $26.3M.
Repurchased 3.7M shares at avg $1.78 in Q3; total 5.7M shares repurchased to date.
Entered co-marketing agreement with Thermo Fisher Scientific for Proteograph suite with Orbitrap Astral mass specs.
Cash, equivalents & investments $312M; FY 2024 revenue guidance reaffirmed at $13-15M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.